| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FZD10 |
| Uniprot No | Q9ULW2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-161aa |
| 氨基酸序列 | ISSMDMERPGDGKCQPIEIPMCKDIGYNMTRMPNLMGHENQREAAIQLHE FAPLVEYGCHGHLRFFLCSLYAPMCTEQVSTPIPACRVMCEQARLKCSPI MEQFNFKWPDSLDCRKLPNKNDPNYLCMEAPNNGSDEPTRGIEGRMDPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK |
| 预测分子量 | 43 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FZD10重组蛋白的3篇参考文献及其简要摘要内容：
---
1. **文献名称**：*"Expression and purification of recombinant FZD10 extracellular domain for structural studies"*
**作者**：Tanaka S, et al.
**摘要**：该研究报道了人源FZD10细胞外结构域的重组表达与纯化方法，通过哺乳动物细胞系统获得可溶性蛋白，并利用X射线晶体学初步解析其结构，为研究FZD10与Wnt配体的相互作用奠定基础。
---
2. **文献名称**：*"FZD10 recombinant protein enhances Wnt/β-catenin signaling in colorectal cancer cells"*
**作者**：Yamamoto H, et al.
**摘要**：作者通过大肠癌细胞模型，验证了外源添加的FZD10重组蛋白能够激活Wnt/β-catenin信号通路，促进肿瘤细胞侵袭性，提示其作为潜在治疗靶点的可能性。
---
3. **文献名称**：*"Development of a FZD10-Fc fusion recombinant protein as a therapeutic agent for ovarian cancer"*
**作者**：Chen L, et al.
**摘要**：研究团队设计并表达了一种FZD10-Fc融合蛋白，通过阻断Wnt配体与内源性受体的结合，抑制卵巢癌细胞增殖，在小鼠模型中显示出抗肿瘤活性。
---
**备注**：以上文献信息为模拟示例，实际引用时需根据具体论文内容调整。建议通过PubMed或Google Scholar检索最新研究。
FZD10 (Frizzled class receptor 10) is a member of the Frizzled family of G protein-coupled receptors that play critical roles in the Wnt signaling pathway, a conserved mechanism regulating embryonic development, cell proliferation, and tissue homeostasis. As a transmembrane receptor, FZD10 binds Wnt ligands, initiating both canonical (β-catenin-dependent) and non-canonical (β-catenin-independent) signaling cascades. Dysregulation of FZD10 has been implicated in various cancers, including colorectal, gastric, and ovarian cancers, where its overexpression correlates with tumor progression, metastasis, and poor prognosis.
Recombinant FZD10 protein is engineered to study its structural and functional properties, often produced in mammalian or insect cell systems to ensure proper post-translational modifications. The protein typically includes the extracellular cysteine-rich domain (CRD), essential for Wnt ligand interaction, and transmembrane regions. Researchers utilize FZD10 recombinant proteins to investigate receptor-ligand binding dynamics, screen therapeutic agents (e.g., monoclonal antibodies or small-molecule inhibitors), and explore mechanisms of Wnt pathway activation in disease models. Its application extends to developing diagnostic tools, as FZD10 overexpression in certain cancers may serve as a biomarker. Additionally, recombinant FZD10 aids in structural studies (e.g., X-ray crystallography) to map binding interfaces and design targeted therapies. Challenges in its use include maintaining native conformational stability and addressing cross-reactivity due to homology with other FZD receptors. Current studies focus on FZD10's role in cancer stem cells and its potential as a therapeutic target for precision oncology.
×
